Suppr超能文献

分析 COVID-19 疫苗加强针在孕妇和哺乳期个体中的反应。

Analysis of Vaccine Reactions After COVID-19 Vaccine Booster Doses Among Pregnant and Lactating Individuals.

机构信息

Department of Obstetrics and Gynecology, University of Washington, Seattle.

Seattle Children's Hospital Research Institute, Department of Pediatrics, University of Washington, Seattle.

出版信息

JAMA Netw Open. 2022 Sep 1;5(9):e2230495. doi: 10.1001/jamanetworkopen.2022.30495.

Abstract

IMPORTANCE

COVID-19 vaccine boosters or third doses are recommended for adolescents and adults who completed their initial COVID-19 vaccine course more than 5 months prior. Minimal data are available on COVID-19 vaccine booster or third dose reactogenicity among pregnant and lactating individuals.

OBJECTIVE

To describe the reactions to the booster or third dose of the COVID-19 vaccine and vaccine experiences among pregnant and lactating individuals.

DESIGN, SETTING, AND PARTICIPANTS: Beginning in October 2021, a follow-up Research Electronic Data Capture (REDCap) survey regarding a COVID-19 vaccine booster or third dose was sent to 17 504 participants in an ongoing online prospective cohort study on COVID-19 vaccines among pregnant and lactating individuals. A convenience sample of adults enrolled in the online prospective study who were pregnant, lactating, or neither pregnant nor lactating at the time of their booster or third dose was eligible for this follow-up survey; 17 014 (97.2%) completed the follow-up survey.

EXPOSURE

Receipt of a booster or third dose of the COVID-19 vaccine.

MAIN OUTCOMES AND MEASURES

Self-reported vaccine reactions less than 24 hours after the dose.

RESULTS

As of April 4, 2022, 17 014 eligible participants (mean [SD] age, 33.3 [3.5] years) responded to the booster or third dose survey; of these, 2009 (11.8%) were pregnant at the time of their booster or third dose, 10 279 (60.4%) were lactating, and 4726 (27.8%) were neither pregnant nor lactating. After a COVID-19 booster or third dose, most individuals (14 074 of 17 005 [82.8%]) reported a local reaction, and 11 542 of 17 005 (67.9%) reported at least 1 systemic symptom. Compared with individuals who were neither pregnant nor lactating, pregnant participants were more likely to report any local reaction to a COVID-19 booster or third dose (adjusted odds ratio [aOR], 1.2; 95% CI, 1.0-1.4; P = .01) but less likely to report any systemic reaction (aOR, 0.7; 95% CI, 0.6-0.8; P < .001). Most pregnant (1961 of 2009 [97.6%]) and lactating (9866 of 10 277 [96.0%]) individuals reported no obstetric or lactation concerns after vaccination.

CONCLUSIONS AND RELEVANCE

This study suggests that COVID-19 vaccine boosters or third doses were well tolerated among pregnant and lactating individuals. Data to evaluate tolerability of boosters or additional doses among pregnant and lactating individuals will be important as they are considered for these populations.

摘要

重要性

对于完成初始 COVID-19 疫苗接种超过 5 个月的青少年和成年人,建议接种 COVID-19 疫苗加强针或第三针。关于孕妇和哺乳期个人接种 COVID-19 疫苗加强针或第三针的反应性的数据很少。

目的

描述孕妇和哺乳期个人接种 COVID-19 疫苗加强针或第三针的反应和疫苗接种体验。

设计、地点和参与者:从 2021 年 10 月开始,一项关于 COVID-19 疫苗加强针或第三针的后续研究电子数据捕获(REDCap)调查发送给了正在进行的一项关于孕妇和哺乳期个人 COVID-19 疫苗的在线前瞻性队列研究中的 17504 名参与者。在加强针或第三针时已参加在线前瞻性研究的成年人中,有资格参加这项随访调查的是怀孕、哺乳或既不怀孕也不哺乳的成年人;其中 17014 人(97.2%)完成了随访调查。

暴露

接种 COVID-19 疫苗加强针或第三针。

主要结果和措施

接种后不到 24 小时报告的疫苗反应。

结果

截至 2022 年 4 月 4 日,17014 名符合条件的参与者(平均[标准差]年龄,33.3[3.5]岁)对加强针或第三针调查做出了回应;其中,2009 名(11.8%)在加强针或第三针时怀孕,10279 名(60.4%)在哺乳,4726 名(27.8%)既不怀孕也不哺乳。在接种 COVID-19 加强针或第三针后,大多数人(17005 人中的 14074 人[82.8%])报告了局部反应,17005 人中的 11542 人(67.9%)报告了至少 1 种全身症状。与既不怀孕也不哺乳的个体相比,孕妇更有可能报告 COVID-19 加强针或第三针接种后的任何局部反应(调整后的优势比[aOR],1.2;95%置信区间[CI],1.0-1.4;P = .01),但不太可能报告任何全身反应(aOR,0.7;95% CI,0.6-0.8;P < .001)。大多数孕妇(2009 名中的 1961 名[97.6%])和哺乳期妇女(10277 名中的 9866 名[96.0%])报告接种疫苗后没有产科或哺乳问题。

结论和相关性

这项研究表明,COVID-19 疫苗加强针或第三针在孕妇和哺乳期人群中耐受性良好。在考虑为这些人群接种加强针或额外剂量时,评估孕妇和哺乳期人群接种加强针或额外剂量的耐受性的数据将非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/490c/9459662/2e9486de6db9/jamanetwopen-e2230495-g001.jpg

相似文献

1
Analysis of Vaccine Reactions After COVID-19 Vaccine Booster Doses Among Pregnant and Lactating Individuals.
JAMA Netw Open. 2022 Sep 1;5(9):e2230495. doi: 10.1001/jamanetworkopen.2022.30495.
2
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
3
COVID-19 Booster Vaccination in Early Pregnancy and Surveillance for Spontaneous Abortion.
JAMA Netw Open. 2023 May 1;6(5):e2314350. doi: 10.1001/jamanetworkopen.2023.14350.
8
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):249-254. doi: 10.15585/mmwr.mm7107e1.
10
Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US.
JAMA Netw Open. 2022 Jul 1;5(7):e2222241. doi: 10.1001/jamanetworkopen.2022.22241.

引用本文的文献

1
A qualitative study on barriers and facilitators of COVID-19 vaccination during pregnancy among pregnant women in Malaysia.
PLoS One. 2025 Aug 8;20(8):e0329895. doi: 10.1371/journal.pone.0329895. eCollection 2025.
4
Safety of and Adverse Reactions to the COVID-19 Vaccine Among Pregnant and Breastfeeding Women.
Med Sci (Basel). 2025 Apr 1;13(2):38. doi: 10.3390/medsci13020038.
5
EudraVigilance insights: Suspected adverse drug reactions in infants through breastfeeding.
Br J Clin Pharmacol. 2025 Aug;91(8):2431-2436. doi: 10.1002/bcp.70063. Epub 2025 Apr 6.
6
Perception of a Novel Group B Streptococcus Vaccine Among Pregnant and Lactating Individuals.
Pediatr Infect Dis J. 2025 Feb 1;44(2S):S149-S152. doi: 10.1097/INF.0000000000004641. Epub 2025 Feb 14.
7
Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living Systematic Review and Meta-analysis.
Drug Saf. 2024 Oct;47(10):991-1010. doi: 10.1007/s40264-024-01458-w. Epub 2024 Jul 15.
8
Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic review.
Vaccine X. 2024 Feb 23;18:100464. doi: 10.1016/j.jvacx.2024.100464. eCollection 2024 Jun.
9
Milk antibody response after 3 COVID-19 vaccine and SARS-CoV-2 infection and implications for infant protection.
iScience. 2023 Aug 29;26(10):107767. doi: 10.1016/j.isci.2023.107767. eCollection 2023 Oct 20.

本文引用的文献

5
Short-term Reactions Among Pregnant and Lactating Individuals in the First Wave of the COVID-19 Vaccine Rollout.
JAMA Netw Open. 2021 Aug 2;4(8):e2121310. doi: 10.1001/jamanetworkopen.2021.21310.
6
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.
N Engl J Med. 2021 Jun 17;384(24):2273-2282. doi: 10.1056/NEJMoa2104983. Epub 2021 Apr 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验